News
T-cell therapy eradicates an aggressive leukemia in 2 children
Two children with an aggressive form of childhood leukemia had a complete remission of their disease - showing no evidence of cancer cells in their bodies - after treatment with a novel cell therapy that reprogrammed their immune...
News
Parkinsons’ drug helps older people to make decisions
A drug widely used to treat Parkinson's Disease can help to reverse age-related impairments in decision making in some older people, a study from researchers at the Wellcome Trust Centre for Neuroimaging has shown. ...
News
Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
New data presented at the 65th annual meeting of the American Academy of Neurology (AAN) show Gilenya® (fingolimod), the first oral disease modifying therapy approved to treat relapsing forms of multiple sclerosis (MS), significantly and consistently reduced the...
News
New study highlights strong anti-cancer properties of soybeans
Soybean meal is a bi-product following oil extraction from soybean seeds. It is rich in protein, which usually makes up around 40% of the nutritional components of the seeds and dependent on the line, and can also contain...
News
Studies for approval of new drugs have insufficient patients to evaluate safety
For medicines intended for chronic use, the number of patients studied before regulatory approval is insufficient to properly evaluate safety and long-term efficacy, requiring the need for new legislation, according to a study by European researchers published in...
News
AstraZeneca to establish strategic R&D centres
AstraZeneca has announced plans to invest in strategic research and development centres in the UK, the US and Sweden to improve pipeline productivity and to establish the company as a global leader in biopharmaceutical innovation. ...
News
Merck announces collaboration with nordic Bioscience for Sprifermin
Merck today announced a strategic alliance with Nordic Bioscience Clinical Development A/S on Merck's investigational drug sprifermin (recombinant human FGF-18) in osteoarthritis (OA) of the knee. This agreement underscores Merck's commitment to osteoarthritis research and development. ...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read